4//SEC Filing
Lee Jennifer Kayden 4
Accession 0001104659-25-015320
CIK 0001649904other
Filed
Feb 18, 7:00 PM ET
Accepted
Feb 19, 9:46 PM ET
Size
14.0 KB
Accession
0001104659-25-015320
Insider Transaction Report
Form 4
Lee Jennifer Kayden
EVP, Head of North America
Transactions
- Exercise/Conversion
Common Stock
2025-02-16+5,500→ 7,893 total - Award
Restricted Stock Units
2025-02-14+36,650→ 36,650 total→ Common Stock (36,650 underlying) - Sale
Common Stock
2025-02-19$57.22/sh−2,035$116,443→ 5,858 total - Award
Stock Options (Right to Buy)
2025-02-14+55,000→ 55,000 totalExercise: $56.69Exp: 2035-02-13→ Common Stock (55,000 underlying) - Exercise/Conversion
Restricted Stock Units
2025-02-16−5,500→ 16,500 total→ Common Stock (5,500 underlying)
Footnotes (5)
- [F1]Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
- [F2]The sales reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction adopted prior to February 27, 2023 solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units.
- [F3]The restricted stock units vest as to 25% of the total shares on each of February 14, 2026, February 14, 2027, February 14, 2028 and February 14, 2029. The restricted stock units have no expiration date.
- [F4]The stock options were granted on February 14, 2025. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.
- [F5]The restricted stock units vest as to 25% of the total shares on each of February 16, 2025, February 16, 2026, February 16, 2027 and February 16, 2028. The restricted stock units have no expiration date.
Documents
Issuer
RHYTHM PHARMACEUTICALS, INC.
CIK 0001649904
Entity typeother
Related Parties
1- filerCIK 0001801372
Filing Metadata
- Form type
- 4
- Filed
- Feb 18, 7:00 PM ET
- Accepted
- Feb 19, 9:46 PM ET
- Size
- 14.0 KB